From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Content Provider	Europe PMC
Author	Mumolo, Maria Gloria Bertani, Lorenzo Ceccarelli, Linda Laino, Gabriella Di Fluri, Giorgia Albano, Eleonora Tapete, Gherardo Costa, Francesco
Copyright Year	2018
Abstract	Fecal calprotectin (FC) has emerged as one of the most useful tools for clinical management of inflammatory bowel diseases (IBD). Many different methods of assessment have been developed and different cut-offs have been suggested for different clinical settings. We carried out a comprehensive literature review of the most relevant FC-related topics: the role of FC in discriminating between IBD and irritable bowel syndrome (IBS) and its use in managing IBD patients In patients with intestinal symptoms, due to the high negative predictive value a normal FC level reliably rules out active IBD. In IBD patients a correlation with both mucosal healing and histology was found, and there is increasing evidence that FC assessment can be helpful in monitoring disease activity and response to therapy as well as in predicting relapse, post-operative recurrence or pouchitis. Recently, its use in the context of a treat-to-target approach led to a better outcome than clinically-based therapy adjustment in patients with early Crohn’s disease. In conclusion, FC measurement represents a cheap, safe and reliable test, easy to perform and with a good reproducibility. The main concerns are still related to the choice of the optimal cut-off, both for differentiating IBD from IBS, and for the management of IBD patients.
ISSN	10079327
Volume Number	24
PubMed Central reference number	PMC6127662
Issue Number	33
PubMed reference number	30197475
Journal	World Journal of Gastroenterology [World J. Gastroenterol]
e-ISSN	22192840
DOI	10.3748/wjg.v24.i33.3681
Language	English
Publisher	Baishideng Publishing Group Inc
Publisher Date	2018-09-01
Access Restriction	Open
Rights License	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Subject Keyword	Fecal calprotectin Inflammatory bowel diseases Crohn’s disease Ulcerative colitis Irritable bowel syndrome
Content Type	Text
Resource Type	Article
Subject	Gastroenterology